Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 8/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20629339 | 0.90 | HDAC2 (0.49) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20629253 | 0.88 | HDAC2 (0.42) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20629473 | 0.81 | HDAC2 (0.49) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20628955 | 0.80 | HDAC6 (0.47) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20629254 | 0.80 | HDAC6 (0.55) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL20605300 | 0.80 | HDAC6 (0.46) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20635876 | 0.78 | MEN1 (0.36) | — | |
| SCHEMBL20629511 | 0.74 | HDAC2 (0.51) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL20629251 | 0.72 | GAA (0.43) | HDAC2HDAC6HDAC8HDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL20610207 | 0.72 | HDAC6 (0.43) | HDAC2HDAC6HDAC8HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | UNIVERSITÄT REGENSBURG (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200308174-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2020-10-01 | — | — | US | disclosed |
| WO-2019007836-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | UNIVERSITÄT REGENSBURG (DE) | 2019-01-10 | — | — | WO | disclosed |
| EP-3424925-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | Universität Regensburg (DE) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198694-B2 | HDAC6 inhibitors, with improved solubility and their uses | HDAC6, HDAC1, HDAC5 | HDAC2 4/4885HDAC6 1/4885HDAC8 6/4885 |
| US-20200308174-A1 | NOVEL HDAC6 INHIBITORS, WITH IMPROVED SOLUBILITY AND THEIR USES | HDAC6, HDAC1, HDAC2 | HDAC2 3/4885HDAC6 1/4885HDAC8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.